Nexalin Technology (NXL) Non Operating Investment Income (2023 - 2026)
Nexalin Technology (NXL) posted Non Operating Investment Income of -$406.0 for Q2 2026, down 561.36% on a QoQ basis from $88.0 in Q1 2026, and down 179.14% year-over-year from $513.0 in Q2 2025.
Powered by 
Analysis
Nexalin Technology (NXL) Non Operating Investment Income (2023 - 2026) Analysis & Trends
Nexalin Technology has reported Non Operating Investment Income for 4 years, with the latest figure at -$406.0 in Q2 2026.
- On a quarterly basis, Non Operating Investment Income fell 179.14% year-over-year to -$406.0 in Q2 2026; TTM through Jun 2026 was -$741.0, a 189.28% decrease from a year earlier, with the FY2025 full-year figure at $919.0, up 950.93% from the prior year.
- Non Operating Investment Income was -$406.0 for Q2 2026 at Nexalin Technology, down from $88.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $41069.0 in Q1 2023, with the low at -$32289.0 in Q3 2023.
- Average Non Operating Investment Income over 4 years is $6.36, with a median of -$50.0 recorded in 2024.
- The largest YoY upside for Non Operating Investment Income was 652.13% in 2025 against a maximum downside of 349.54% in 2025.
- Over 4 years, Non Operating Investment Income stood at -$1205.0 in 2023, then jumped by 84.4% to -$188.0 in 2024, then surged by 652.13% to $1038.0 in 2025, then tumbled by 139.11% to -$406.0 in 2026.
- The last three Non Operating Investment Income figures came in at -$406.0 (Q2 2026), $88.0 (Q1 2026), and $1038.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.84 Bn | 174.23 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 128.02 Bn | 122.81 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.28 Bn | 108.46 Bn | 6.34 Bn | - |
| 4 | Stryker | 103.92 Bn | 100.44 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 63.51 Bn | 62.97 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 49.96 Bn | 45.70 Bn | 1.35 Bn | - |
| 7 | Alcon | 32.86 Bn | 31.40 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.25 Bn | 30.30 Bn | 830.00 Mn | - |
| 9 | Steris | 20.74 Bn | 20.26 Bn | 684.20 Mn | - |
| 10 | Nexalin Technology | 3.42 Mn | 2.41 Mn | 8,897.00 | -406.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -406.00 |
| Mar 31, 2026 | 88.00 |
| Dec 31, 2025 | 1,038.00 |
| Sep 30, 2025 | -1,461.00 |
| Jun 30, 2025 | 513.00 |
| Mar 31, 2025 | 830.00 |
| Dec 31, 2024 | -188.00 |
| Sep 30, 2024 | -325.00 |
| Jun 30, 2024 | 245.00 |
| Mar 31, 2024 | 160.00 |
| Dec 31, 2023 | -1,205.00 |
| Sep 30, 2023 | -32,289.00 |
| Jun 30, 2023 | -7,980.00 |
| Mar 31, 2023 | 41,069.00 |